ALX-001 is under clinical development by Allyx Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ALX-001 overview

ALX-001 is under development for the treatment Alzheimer’s disease (AD). The drug candidate is silent allosteric modulator (SAM). It acts by targeting mGLUR5.

Allyx Therapeutics overview

Allyx Therapeutics is a biotechnology company that focuses on the discovery and development of a unique disease modifying treatment for the treatment of Alzheimer’s disease. Allyx Therapeutics is headquartered in New Haven, Connecticut, the US.

For a complete picture of ALX-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.